AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04293822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Minoxidil 5% gel
Study NCT03238495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere, Carboplatin, Herceptin + Pertuzumab
Description: TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
Study NCT03238495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere, Carboplatin, Herceptin + Pertuzumab
Description: TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
Study NCT03238495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
Study NCT03645993 — intervention group
Intervention type: GENETIC
Intervention: Genetic Testing
Description: A one time blood sample will be taken.
Study NCT03563378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
Study NCT03563378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Patients will be administered normal saline for intraoperative fluid management.
Study NCT03182270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nCLE
Description: Procedure: EUS-FNA Device: nCLE
Study NCT00205855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision SCS
Description: Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
Study NCT02164461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axalimogene filolisbac
Study NCT00265538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient educational letter to engage provider in hypertension rx discussion
Description: Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.
Study NCT04296448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellscope
Description: Cellphone otoscope (Cellscope) to evaluate pediatric patient ears.
Study NCT02666625 — intervention group
Intervention type: PROCEDURE
Intervention: saliva samples
Study NCT02666625 — intervention group
Intervention type: PROCEDURE
Intervention: blood samples
Study NCT01455636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Sanitizer
Description: The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
Study NCT01455636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Improved Micronutrient Powder
Description: A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
Study NCT00265538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive (Arms B and C) and health educator phone call (Arm C)
Description: Patients may receive a financial incentive for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the financial incentive discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt. The Financial incentive is part of both Arms B and C. The health educator phone call is only in Arm C.
Study NCT00427609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bicillin L-A
Description: Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
Study NCT00427609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicillin L-A
Description: Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
Study NCT04486092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Study NCT01157975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone will be taken at a dose of 30 mg for up to 14 days
Study NCT01157975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be taken at a dose of 40 mg for up to 4 days
Study NCT02249143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP and room air
Description: Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
Study NCT01555528 — intervention group
Intervention type: DEVICE
Intervention: easypod™
Description: Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
Study NCT03388411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiome profiling
Description: Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
Study NCT02401828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Switch from combination antiretroviral therapy to dolutegravir monotherapy
Study NCT01455636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No hand sanitizer
Description: All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.~No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed
Study NCT01455636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Micronutrient Powder
Description: I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
Study NCT01455636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No Micronutrient Powder
Description: I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
Study NCT01664728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
Study NCT01664728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
Study NCT03572595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 FDG-PET/CT
Description: imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
Study NCT03111628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omalizumab
Description: omalizumab 300 mg every 4 weeks by subcutaneous injection
Study NCT01920685 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety intervention
Study NCT01920685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety intervention
Study NCT00956670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00956670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03970915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body warmer
Description: The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
Study NCT03970915 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard warming procedure
Description: Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
Study NCT00956670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study of High Risk Factors
Description: Undergo lymphedema assessment
Study NCT00956670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT00956670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Laparoscopic Surgery
Description: Undergo surgery
Study NCT00956670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Lymphadenectomy
Description: Undergo lymphadenectomy
Study NCT02314546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xylocaine
Description: Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
Study NCT02314546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Placebo - Control patients will receive intranasal saline.
Study NCT02397629 — intervention group
Intervention type: OTHER
Intervention: This study has no intervention
Study NCT01026935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open inguinal hernia repair
Description: Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
Study NCT00333099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Impact (R) Enteral Nutrition
Description: mucositis frequency, treatment tolerance
Study NCT02599701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: A single dose Gabapentin 300mg at bedtime.
Study NCT02599701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single placebo dose with the same physical characteristics of the active intervention.
Study NCT03858673 — intervention group
Intervention type: PROCEDURE
Intervention: VTH via the Tsuzi method with residual uterine ligament ligation
Description: VTH via the Tsuzi method with residual uterine ligament ligation
Study NCT02579070 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DFUPS
Description: The DFUPS device is a two-camera instrument for capturing images of feet.
Study NCT02579070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DFUPS
Description: The DFUPS device is a two-camera instrument for capturing images of feet.
Study NCT02394873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Dressing for second-degree burn wound.
Study NCT05223946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Radiometry
Description: The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.
Study NCT05223946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microwave Radiometry
Description: The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.
Study NCT05223946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENAR-CHENS-01
Description: Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
Study NCT05223946 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Combination Therapy
Description: ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )
Study NCT05223946 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Traditional Combination Therapy
Description: ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )
Study NCT03081520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective response MIT
Description: Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
Study NCT03081520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective response HAIT
Description: Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
Study NCT03081520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective response HIIT
Description: Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
Study NCT04199637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TVG
Description: Therapeutic video game
Study NCT02536989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
Study NCT01268735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubricating eyedrops containing hydroxypropyl-guar
Description: Eyedrops BID
Study NCT00109343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: ProQuad™ (V221)
Description: 0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
Study NCT00109343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
Description: 0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
Study NCT01723059 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Triple Therapy
Description: for 10 days
Study NCT01723059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Therapy
Description: total 10 days
Study NCT02746861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Supported DSMS
Description: Phone, SMS/text, and smartphone-based intervention.
Study NCT02536989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
Study NCT03997955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial induction
Description: Myofascial induction in plantar fascia
Study NCT03997955 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham myofascial induction
Description: Sham myofascial induction in plantar fascia
Study NCT02212067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
Study NCT02212067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
Study NCT02266017 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Coping Skills Training
Study NCT02266017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training
Study NCT00480116 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Hepatitis B vaccine Lot 1
Description: 20 µg, IM, month 0 and 1
Study NCT00480116 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Hepatitis B vaccine Lot 2
Description: 20µg, IM, month 0 and 1
Study NCT00480116 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Hep B vaccine Lot 3
Description: 20µg, IM, month 0 and 1
Study NCT04233684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rapid urease test
Description: Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H\&E stain and Giemsa stain Gold standard is a immunohistochemistry.
Study NCT00870727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole oral product
Description: Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
Study NCT00333099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: impact
Description: 1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment
Study NCT03381638 — intervention group
Intervention type: DEVICE
Intervention: Blink Reflexometer
Description: The device uses 5 light puffs of air to the side of the eye causing a blink reflex that is captured by the high-speed camera tracking the eyelids.
Study NCT00870727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be identical in size and appearance to study drug.
Study NCT01881464 — intervention group
Intervention type: DEVICE
Intervention: Endopath from Itamar medical - FDA approved device.
Description: endothelial function assessment by Endopath device
Study NCT01881464 — intervention group
Intervention type: DRUG
Intervention: Anti TNF Alfa.
Description: This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
Study NCT00533442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
Study NCT00533442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: MMF 1 gm BID beginning 1st day postoperative day
Study NCT00533442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Part of standard maintenance.
Study NCT00533442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Part of standard maintenance.
Study NCT00533442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Part of standard maintenance
Study NCT00533442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Part of standard maintenance
Study NCT03186170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSA sperm selection
Description: The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
Study NCT03186170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SSA sperm selection
Description: The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
Study NCT01858077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB BVS™
Description: Bioresorbable scaffold
Study NCT01544881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin Inhalation Powder
Description: Inhalation Powder using the Gen2C inhaler
Study NCT01544881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Acting Analog
Description: Subcutaneous Injection